The forward P/E of 38.1x implies the market expects earnings to grow roughly 30% over the next year, which aligns with the recent acceleration in organic growth but leaves little room for disappointment. The PEG of 6.06 is elevated, indicating that the current price already discounts a prolonged period of above-average growth. Investors should monitor whether the GLP-1 and biologics tailwinds can justify this premium relative to more diversified packaging peers.

The sequential improvement from 35.1% gross margin in 2026Q1 suggests that the mix shift is accelerating, likely due to increased adoption of GLP-1 elastomers and biologics components. Operating margin of 20.5% is near the top of the trailing ten-quarter range, indicating strong operating leverage. However, the mid-2026 contract manufacturing wind-down could pressure margins if lower-margin contract volumes are replaced by higher-margin proprietary products, which would be a positive mix shift but may create revenue volatility.

The consistency of ROIC around 4.8% indicates that the massive investment in production capacity is not yet diluting returns, but it also implies that the company is not generating incremental returns above its cost of capital. The asset turnover of 0.21x is low, reflecting the capital-intensive nature of the business, but the high gross margins compensate. If the new capacity is fully utilized, ROIC could improve, but investors should watch for under-absorption during the contract wind-down period.

DSO increased from 67 days in 2026Q1 to 73 days in 2026Q2, which may indicate a shift in customer mix or payment terms, but it remains within historical norms. DIO also ticked up to 75 days, reflecting higher inventory levels to support growth. The stable DPO of 42 days suggests WST is not stretching supplier payments, which is consistent with its conservative balance sheet. The lengthening CCC is a modest drag on cash flow, but the company's strong liquidity position mitigates any concern.

The company's conservative leverage is a strategic asset, allowing it to fund large-scale capex internally and weather demand shocks. The low D/EBITDA of 1.74x suggests that even if EBITDA declines due to the contract wind-down, debt service remains comfortable. However, the high valuation multiple means that any increase in leverage to fund M&A could be viewed negatively by the market. Investors should monitor whether management maintains this fortress balance sheet or becomes more aggressive in capital deployment.

The liquidity position is strong, with current assets covering nearly three times current liabilities. The quick ratio of 2.12 indicates that even without selling inventory, WST can meet its short-term obligations. This buffer is particularly valuable given the upcoming contract manufacturing wind-down, which could cause temporary cash flow disruptions. The company's ability to self-fund its capex program without straining liquidity is a key strength, but investors should watch for any deterioration in the current ratio if working capital needs increase.